Results 171 to 180 of about 1,339,212 (357)
Controlled Comparison of Oral Twice-weekly and Oral Daily Isoniazid plus PAS in Newly Diagnosed Pulmonary Tuberculosis [PDF]
, 1973 A controlled clinical trial was undertaken in 247 patients with newly diagnosed pulmonary tuberculosis to assess the relative efficacies of a fully supervised twice-weekly oral regimen of isoniazid plus PAS (para-aminosalicylic acid) and a standard ...
Tuberculosis Chemotherapy Centre, Madras
core
ChemBioChem, EarlyView.The study characterizes interactions between DnaB helicase and DnaG primase in Mycobacterium tuberculosis using small‐angle X‐ray scattering, surface plasmon resonance, and cross‐linking. The findings reveal that DnaG forms dimers in solution, which are destabilized upon DnaB binding.
Dayan A, Ilic S, Akabayov B
wiley +1 more source
A Further Report on Lung Resection for Pulmonary Tuberculosis [PDF]
, 1952 B. J. Bickford +4 more
openalex +1 more source
Seven year findings of short-course chemotherapy in 18 districts in India under district tuberculosis programme [PDF]
, 1996 The ICMR undertook a study project to find out the feasibility of introducing Short-Course Chemotherapy (SCC) under the existing programme conditions and evaluate its acceptability.
Tuberculosis Research Centre , Madras
core
ChemBioChem, EarlyView.Cyclometalated gold(III) complexes offer a versatile platform for selective biological interactions, including cysteine arylation, redox modulation, and enzyme inhibition. This review explores their roles in anticancer, antimicrobial, and protein modification strategies, highlighting their ability to disrupt metabolic pathways, modulate aquaporins, and
Sophie R. Thomas, Riccardo Bonsignore
wiley +1 more source
THE CHEMOTHERAPY OF EXPERIMENTAL TUBERCULOSIS II [PDF]
, 1950 Dorothy Hamre +2 more
openalex +1 more source
ChemBioChem, EarlyView.Bacillus Calmette–Guérin (BCG) immunotherapy is the gold standard for nonmuscle invasive bladder cancer (NMIBC). However, it is limited by adverse effects and resistance, despite eliciting a robust immune response. This proof‐of‐concept study explores Antigen 85‐mediated, metabolically with trehalose‐PEG4 mertansine‐labeled BCG as a novel treatment ...
Michael Grimmeisen +10 more
wiley +1 more source